Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 25

1.

Genetic Evaluation of Schizophrenia Using the Illumina HumanExome Chip.

Moons T, De Hert M, Gellens E, Gielen L, Sweers K, Jacqmaert S, van Winkel R, Vandekerckhove P, Claes S.

PLoS One. 2016 Mar 30;11(3):e0150464. doi: 10.1371/journal.pone.0150464. eCollection 2016.

2.

Knowledge of Psychiatric Nurses About the Potentially Lethal Side-Effects of Clozapine.

De Hert M, De Beugher A, Sweers K, Wampers M, Correll CU, Cohen D.

Arch Psychiatr Nurs. 2016 Feb;30(1):79-83. doi: 10.1016/j.apnu.2015.09.003. Epub 2015 Sep 25.

PMID:
26804506
3.

Attitudes of Psychiatric Nurses about the Request for Euthanasia on the Basis of Unbearable Mental Suffering(UMS).

De Hert M, Van Bos L, Sweers K, Wampers M, De Lepeleire J, Correll CU.

PLoS One. 2015 Dec 23;10(12):e0144749. doi: 10.1371/journal.pone.0144749. eCollection 2015.

4.

End-of-life (care) perspectives and expectations of patients with schizophrenia.

Sweers K, Dierckx de Casterlé B, Detraux J, De Hert M.

Arch Psychiatr Nurs. 2013 Oct;27(5):246-52. doi: 10.1016/j.apnu.2013.05.003. Epub 2013 Jun 10.

PMID:
24070994
5.

Diabetes, physical activity participation and exercise capacity in patients with schizophrenia.

Vancampfort D, De Hert M, Sweers K, De Herdt A, Detraux J, Probst M.

Psychiatry Clin Neurosci. 2013 Sep;67(6):451-6. doi: 10.1111/pcn.12077. Epub 2013 Aug 13.

6.

Relationships between physical fitness, physical activity, smoking and metabolic and mental health parameters in people with schizophrenia.

Vancampfort D, Probst M, Scheewe T, De Herdt A, Sweers K, Knapen J, van Winkel R, De Hert M.

Psychiatry Res. 2013 May 15;207(1-2):25-32. doi: 10.1016/j.psychres.2012.09.026. Epub 2012 Oct 7.

PMID:
23051886
7.

Body weight and metabolic adverse effects of asenapine, iloperidone, lurasidone and paliperidone in the treatment of schizophrenia and bipolar disorder: a systematic review and exploratory meta-analysis.

De Hert M, Yu W, Detraux J, Sweers K, van Winkel R, Correll CU.

CNS Drugs. 2012 Sep 1;26(9):733-59. doi: 10.2165/11634500-000000000-00000. Review.

PMID:
22900950
8.

Atomic force microscopy under controlled conditions reveals structure of C-terminal region of α-synuclein in amyloid fibrils.

Sweers KK, van der Werf KO, Bennink ML, Subramaniam V.

ACS Nano. 2012 Jul 24;6(7):5952-60. doi: 10.1021/nn300863n. Epub 2012 Jun 20.

PMID:
22695112
9.

Nanomechanical properties of single amyloid fibrils.

Sweers KK, Bennink ML, Subramaniam V.

J Phys Condens Matter. 2012 Jun 20;24(24):243101. doi: 10.1088/0953-8984/24/24/243101. Epub 2012 May 15. Review.

PMID:
22585542
10.

Spatially resolved frequency-dependent elasticity measured with pulsed force microscopy and nanoindentation.

Sweers KK, van der Werf KO, Bennink ML, Subramaniam V.

Nanoscale. 2012 Mar 21;4(6):2072-7. doi: 10.1039/c2nr12066f. Epub 2012 Feb 13.

PMID:
22331128
11.

Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders--a systematic review and meta-analysis.

Mitchell AJ, Vancampfort D, Sweers K, van Winkel R, Yu W, De Hert M.

Schizophr Bull. 2013 Mar;39(2):306-18. doi: 10.1093/schbul/sbr148. Epub 2011 Dec 29. Review.

12.

Metaphor interpretation and use: a window into semantics in schizophrenia.

Elvevåg B, Helsen K, De Hert M, Sweers K, Storms G.

Schizophr Res. 2011 Dec;133(1-3):205-11. doi: 10.1016/j.schres.2011.07.009. Epub 2011 Aug 6.

PMID:
21821395
13.

Guidelines for screening and monitoring of cardiometabolic risk in schizophrenia: systematic evaluation.

De Hert M, Vancampfort D, Correll CU, Mercken V, Peuskens J, Sweers K, van Winkel R, Mitchell AJ.

Br J Psychiatry. 2011 Aug;199(2):99-105. doi: 10.1192/bjp.bp.110.084665. Review.

14.

Walking capacity is associated with health related quality of life and physical activity level in patients with schizophrenia: a preliminary report.

Martín-Sierra A, Vancampfort D, Probst M, Bobes J, Maurissen K, Sweers K, De Schepper E, De Hert M.

Actas Esp Psiquiatr. 2011 Jul-Aug;39(4):211-6. Epub 2011 Jul 1. English, Spanish.

15.

Nanomechanical properties of α-synuclein amyloid fibrils: a comparative study by nanoindentation, harmonic force microscopy, and Peakforce QNM.

Sweers K, van der Werf K, Bennink M, Subramaniam V.

Nanoscale Res Lett. 2011 Mar 30;6(1):270. doi: 10.1186/1556-276X-6-270.

16.

Quality assessment of physical activity recommendations within clinical practice guidelines for the prevention and treatment of cardio-metabolic risk factors in people with schizophrenia.

Vancampfort D, Sweers K, Probst M, Mitchell AJ, Knapen J, De Hert M.

Community Ment Health J. 2011 Dec;47(6):703-10. doi: 10.1007/s10597-011-9431-8. Epub 2011 Jun 21. Review.

PMID:
21691822
17.

Lack of physical activity during leisure time contributes to an impaired health related quality of life in patients with schizophrenia.

Vancampfort D, Probst M, Scheewe T, Maurissen K, Sweers K, Knapen J, De Hert M.

Schizophr Res. 2011 Jul;129(2-3):122-7. doi: 10.1016/j.schres.2011.03.018. Epub 2011 Apr 14.

PMID:
21493044
18.

Eurofit test battery in patients with schizophrenia or schizoaffective disorder: reliability and clinical correlates.

Vancampfort D, Probst M, Sweers K, Maurissen K, Knapen J, Willems JB, Heip T, De Hert M.

Eur Psychiatry. 2012 Aug;27(6):416-21. doi: 10.1016/j.eurpsy.2011.01.009. Epub 2011 Mar 12.

PMID:
21398095
19.

Association of the metabolic syndrome with physical activity performance in patients with schizophrenia.

Vancampfort D, Sweers K, Probst M, Maurissen K, Knapen J, Minguet P, De Hert M.

Diabetes Metab. 2011 Sep;37(4):318-23. doi: 10.1016/j.diabet.2010.12.007. Epub 2011 Mar 9.

20.

Prevalence and severity of antipsychotic related constipation in patients with schizophrenia: a retrospective descriptive study.

De Hert M, Dockx L, Bernagie C, Peuskens B, Sweers K, Leucht S, Tack J, Van de Straete S, Wampers M, Peuskens J.

BMC Gastroenterol. 2011 Mar 8;11:17. doi: 10.1186/1471-230X-11-17.

Items per page

Supplemental Content

Loading ...
Write to the Help Desk